AMAM AMBRX BIOPHARMA INC

Ambrx Biopharma to Host Corporate Update Conference Call

Ambrx Biopharma to Host Corporate Update Conference Call

Conference call to discuss outcome of the strategic review that was initiated in August 2022

SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company’s strategic review of its development pipeline.

Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company’s website at: .

To access the call by phone, please use the registration link on the investor relations section of the website, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A webcast replay will be available in the investor relations section of the company’s website for 90 days following the completion of the call.

About Ambrx Biopharma Inc. (Ambrx)

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit .

Contacts

INVESTORS

Laurence Watts

Managing Director

Gilmartin Group, LLC.

619-916-7620

MEDIA

Source: Ambrx, Inc.



EN
11/10/2022

Underlying

AMAMAMBRX BIOPHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AMBRX BIOPHARMA INC

 PRESS RELEASE
Free
AMAM AMBRX BIOPHARMA...

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

Ambrx Shareholders Approve Acquisition by Johnson & Johnson SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O’Connor, Chief Executive Officer of Ambrx, said, “We want t...

March 6, 2024 1 EN
 PRESS RELEASE
Free
AMAM AMBRX BIOPHARMA...

Ambrx Announces Sale to Johnson & Johnson

Ambrx Announces Sale to Johnson & Johnson SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. “We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unm...

January 8, 2024 1 EN
 PRESS RELEASE
Free
AMAM AMBRX BIOPHARMA...

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI) SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. “2023 has been a transformational year for Ambrx, especially for our publicly held securities. We voluntarily transferred to Nasdaq from the New York Stock Exchange, we changed our parent company domicile to Delaware from the Cayman Islands and we terminated our ADS program, resul...

December 14, 2023 1 EN
 PRESS RELEASE
Free
AMAM AMBRX BIOPHARMA...

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalat...

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose Cohort 8 The cohort (2.88 mg/kg) is now fully enrolled with 20 patients Recommended phase 2 dose expected by early nex...

November 28, 2023 1 EN
 PRESS RELEASE
Free
AMAM AMBRX BIOPHARMA...

Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising ...

Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments Newly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at therapeutic doses of 2.0 – 2.88 mg/kg (Cohorts 6-8) in heavily pretreated patients (median of 4 and maximum of 13 prior lines of therapy): 52% (12/23) of patient...

October 23, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch